Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001651308-24-000145
Filing Date
2024-10-31
Accepted
2024-10-31 17:40:59
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 6067
  Complete submission text file 0001651308-24-000145.txt   8031
Mailing Address 47 THORNDIKE STREET SUITE B1-1 CAMBRIDGE MA 02142
Business Address 47 THORNDIKE STREET SUITE B1-1 CAMBRIDGE MA 02142 617 252 4343
LEAP THERAPEUTICS, INC. (Subject) CIK: 0001509745 (see all company filings)

EIN.: 274412575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-90188 | Film No.: 241416377
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filed by) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)